Navigation Links
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Date:3/7/2012

LA JOLLA, CA - Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

"I am excited that our scientific findings will help save lives," said Charles Cochrane, MD, professor emeritus at Scripps Research. "Many years of work in our basic research laboratory at The Scripps Research Institute made this landmark development possible."

Respiratory distress syndrome (also known as neonatal respiratory distress syndrome) is a life-threatening condition affecting pre-term infants. The more premature an infant is, the more likely he or she is to suffer from it and die.

The condition occurs when infants are born prior to the time when natural surfactant is made in their lungs. Surfactant is a liquid that coats the inside of the lungs, helping to keep the air sacs open and making normal breathing possible. Without enough surfactant, the lungs collapse and the body can be starved of oxygen.

In addition to mechanical ventilation, current treatments for pre-term infants involve using surfactants derived from chopped cow or pig lungs. However, animal-derived surfactants are expensive, contain material that can be injurious to the lungs, and cannot be produced in quantities sufficient to treat pre-term infants worldwide. In addition, animal-derived surfactants can only be used once since they cause an immune reaction; in contrast, the new synthetic surfactant is not immunogenic.

The Cochrane lab first created a synthetic version of surfactant in the 1990s, mimicking a natural peptide known as Surfactant Protein B; the inventors of the technology are Cochrane and Susan Revak. After this formative work at Scripps Research, the therapy was developed by Discovery Labs of Warrington, PA, which oversaw the three phases of clinical trials required by the FDA. These clinic trials pro
'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
Scripps Research Institute
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
(Date:4/22/2014)... of Montana,s Wildlife Biology Program, co-wrote a research paper published ... of Sciences on how streamwater chemistry varies across a ... Lowe and co-authors from ... the Cary Institute of Ecosystem Studies, the University of Connecticut ... water samples collected every 10 meters along 32 tributaries of ...
(Date:4/22/2014)... HOUSTON (April 22, 2014) Biotechnology scientists must ... for new patent and licensing guidelines, according to a ... Policy. , Published in the current issue of the ... on the June 2013 U.S. Supreme Court ruling in ... Genetics that naturally occurring genes are unpatentable. The court ...
(Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
Breaking Biology News(10 mins):New research focuses on streamwater chemistry, landscape variation 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... adults with the blood cancer mixed-lineage leukemia (MLL) typically have ... birthdays. Although there are varying causes of MLL, most cases ... and the AF4 genes. When the ... cancer-causing oncogene is created. Although researchers have known that the ...
... engineering holds great promise for the treatment of conditions ... injuries. However, bone and cartilage currently produced in ... the body so they,re not clinically viable. Dr. ... of Medicine & Dentistry at The University of Western ...
... 2008 -- A rat thought extinct for 11 million years ... new species discovered in the Greater Mekong Region of Southeast ... launched by World Wildlife Fund (WWF). First ... discovered or newly identified by science between 1997 and 2007 ...
Cached Biology News:Tracking the molecular pathway to mixed-lineage leukemia 2Building better bones and tissue in the lab 2Over 1,000 species discovered in the Greater Mekong in past decade 2
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Licensing Opportunities , , ... KANSAS CITY, Mo. , May 17 ... Inc., today announced that it is continuing its strategic international expansion ... group of leading research hospitals and institutes based in Toronto, ...
... , May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris ... drug development company specialized in oncology and endocrinology, today ... orphan medicinal product designation from the Committee for Orphan ... its compound AEZS-108 for the treatment of ovarian cancer. ...
... China, May 17 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (Nasdaq: ... of a leading over-the-counter Hepatitis B medicine, Xin,Aoxing Oleanolic Acid ... financial results of the first quarter ended March,31, 2010 ... increased 66.0% to $12.4 million, -- Q1 ...
Cached Biology Technology:The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 2The iBridge Network Adds Toronto's University Health Network as First Canadian Partner 3Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 2Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 2Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 3Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 4Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 5Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 6Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 7Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 8Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 9Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 10Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 11Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 12Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results 13
... a user-friendly statistical software package for scientists ... statistical analysis without being a statistical expert.Just ... and research and SigmaStat suggests the appropriate ... tests underlying assumptions and suggests another test ...
... Novexin offers bespoke, cost-effective solutions for complex protein ... extensive expertise and experience to help you develop a ... , , ... , transfer all methodology ...
... is a chemiluminescent signal enhancing reagent ... boost the signal obtained with all ... ChemiLucent™ Plus is derived from a ... complex- or chemiluminescent substrate enhancers, ChemiLucent™ ...
... GeneSpring Workgroup solution is a highly ... mining expression data in a workgroup ... deployed in over 40 leading pharmaceutical, ... worldwide. GeneSpring Workgroup streamlines genomics research ...
Biology Products: